Entering text into the input field will update the search result below

Atea downgraded at JPMorgan on shrinking COVID opportunity

Aug. 10, 2023 10:20 AM ETAtea Pharmaceuticals, Inc. (AVIR)PFE, MRKBy: Dulan Lokuwithana, SA News Editor1 Comment
Corona Virus

loops7/E+ via Getty Images

  • Atea Pharmaceuticals (NASDAQ:AVIR) traded lower on Thursday after JPMorgan downgraded the antiviral developer to Underweight from Neutral, citing a limited market opportunity for its lead product candidate, bemnifosbuvir, in COVID-19.
  • Bemnifosbuvir, a nucleotide polymerase inhibitor designed as an oral therapy, is currently

Recommended For You

Comments (1)

Have a tip? Submit confidentially to our News team. Found a factual error? Report here.

Fangorn profile picture
no interest in Atea

About AVIR

SymbolLast Price% Chg
Market Cap
Yield (TTM)
Rev Growth (YoY)
Short Interest
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
Atea Pharmaceuticals, Inc.
Xeris Biopharma Holdings, Inc.
Nuvation Bio Inc.
Terns Pharmaceuticals, Inc.
EyePoint Pharmaceuticals, Inc.
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.